| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ... The Lancet 384 (9938), 164-172, 2014 | 4695 | 2014 |
| Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement ES Kim, SS Bruinooge, S Roberts, G Ison, NU Lin, L Gore, TS Uldrick, ... Journal of Clinical Oncology 35 (33), 3737-3744, 2017 | 435 | 2017 |
| Pathological complete response and accelerated drug approval in early breast cancer TM Prowell, R Pazdur New England Journal of Medicine 366 (26), 2438-2441, 2012 | 416 | 2012 |
| Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research brain metastases working group NU Lin, T Prowell, AR Tan, M Kozak, O Rosen, L Amiri-Kordestani, ... Journal of Clinical Oncology 35 (33), 3760-3773, 2017 | 351 | 2017 |
| FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma VE Kwitkowski, TM Prowell, A Ibrahim, AT Farrell, R Justice, SS Mitchell, ... The oncologist 15 (4), 428-435, 2010 | 306 | 2010 |
| CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis JJ Gao, J Cheng, E Bloomquist, J Sanchez, SB Wedam, H Singh, ... The Lancet Oncology 21 (2), 250-260, 2020 | 260 | 2020 |
| Current status and future perspectives on neoadjuvant therapy in lung cancer GM Blumenthal, PA Bunn Jr, JE Chaft, CE McCoach, EA Perez, ... Journal of Thoracic Oncology 13 (12), 1818-1831, 2018 | 204 | 2018 |
| Abstract s1-11: Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (ctneobc) P Cortazar, L Zhang, M Untch, K Mehta, J Costantino, N Wolmark, ... Cancer Research 72 (24_Supplement), S1-11-S1-11, 2012 | 155 | 2012 |
| FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer P Narayan, TM Prowell, JJ Gao, LL Fernandes, E Li, X Jiang, J Qiu, J Fan, ... Clinical Cancer Research 27 (7), 1842-1849, 2021 | 134 | 2021 |
| Seamless oncology-drug development TM Prowell, MR Theoret, R Pazdur New England Journal of Medicine 374 (21), 2001-2003, 2016 | 115 | 2016 |
| What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? TM Prowell, NE Davidson The oncologist 9 (5), 507-517, 2004 | 95 | 2004 |
| Outcomes of older women with hormone receptor–positive, human epidermal growth factor receptor–negative metastatic breast cancer treated with a CDK4/6 inhibitor and an … LJ Howie, H Singh, E Bloomquist, S Wedam, L Amiri-Kordestani, S Tang, ... Journal of Clinical Oncology 37 (36), 3475-3483, 2019 | 76 | 2019 |
| A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer MJ Higgins, TM Prowell, AL Blackford, C Byrne, NF Khouri, SA Slater, ... Breast cancer research and treatment 131, 915-924, 2012 | 72 | 2012 |
| Seamless designs: current practice and considerations for early-phase drug development in oncology BP Hobbs, PC Barata, Y Kanjanapan, CJ Paller, J Perlmutter, GR Pond, ... JNCI: Journal of the National Cancer Institute 111 (2), 118-128, 2019 | 65 | 2019 |
| US FDA drug approvals for breast cancer: a decade in review S Arora, P Narayan, CL Osgood, S Wedam, TM Prowell, JJ Gao, M Shah, ... Clinical Cancer Research 28 (6), 1072-1086, 2022 | 52 | 2022 |
| Expansion cohorts in first-in-human solid tumor oncology trials MR Theoret, LH Pai-Scherf, MK Chuk, TM Prowell, S Balasubramaniam, ... Clinical Cancer Research 21 (20), 4545-4551, 2015 | 39 | 2015 |
| Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond T Bao, T Prowell, V Stearns American journal of therapeutics 13 (4), 337-348, 2006 | 34 | 2006 |
| Residual disease after neoadjuvant therapy—developing drugs for high-risk early breast cancer TM Prowell, JA Beaver, R Pazdur New England Journal of Medicine 380 (7), 612-615, 2019 | 31 | 2019 |
| Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole TM Prowell, AL Blackford, C Byrne, NF Khouri, M Dowsett, E Folkerd, ... Cancer Prevention Research 4 (12), 1993-2001, 2011 | 31 | 2011 |
| Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus … JJ Gao, J Cheng, TM Prowell, E Bloomquist, S Tang, SB Wedam, ... The Lancet Oncology 22 (11), 1573-1581, 2021 | 30 | 2021 |
